Celularity Seeks Nasdaq Approval for Convertible Note Shares; 10% Price Cut if Vote Fails
CELU sits 75% above its 52-week low of $0.56 on light trading volume (0.1× avg).
Summary
Celularity's preliminary proxy asks shareholders to approve the full share issuance under its September 2026 convertible note financing for Nasdaq purposes, with a 10% conversion and exercise price cut triggered if approval is not obtained by December 19, 2026.
Key Events · Financing and Capital Events · CELU
-
Nasdaq Vote on Convertible Note Shares
Shareholders are asked to approve, for Nasdaq Listing Rule 5635, the full issuance of Class A common stock upon conversion of the notes and exercise of the warrants from the September 23, 2026 Securities Purchase Agreement, which allows up to $25.0 million of senior secured convertible notes in two tranches.
-
10% Price Cut if Vote Fails
If the required stockholder approval is not obtained on or prior to December 19, 2026, the then-current conversion price of each outstanding note and exercise price of each outstanding warrant automatically drops 10%, effective December 20, 2026 — increasing the shares issuable.
-
Initial Tranche Already Funded
The initial closing on September 24, 2026 issued roughly $11.01 million of notes convertible into about 7,340,000 shares plus warrants for about 4,037,000 shares, all at an initial $1.50 conversion and exercise price versus today's $0.98 stock price.
-
Equity Plan Reserve Increase
A separate proposal would add 3,500,000 shares to the 2021 Equity Incentive Plan, raising the reserve to 4,479,204 shares; only 178,154 shares remained available as of December 31, 2025.
Analysis · CELU · Life Sciences
Celularity is asking shareholders to bless the full share issuance behind its September 2026 convertible financing, a Nasdaq Rule 5635(d) requirement rather than a new deal. The stakes are concrete: if approval is not in hand by December 19, 2026, every outstanding note conversion price and warrant exercise price drops 10% automatically on December 20, 2026, so a failed vote directly increases the share count issued to the lenders. Because the notes are already binding obligations, a 'no' vote does not undo the debt — it only limits how many shares the company can deliver and makes the eventual conversion cheaper for the holders. Against a going-concern backdrop with only $0.6M of cash reported in the Q2 2026 10-Q, the proxy also asks for 3,500,000 more shares under the 2021 Equity Incentive Plan, adding a second layer of dilution on top of the financing.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.5M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.